JP5553769B2 - 皮膚創傷治癒のためのエリスロポエチンの局所適用および製剤 - Google Patents

皮膚創傷治癒のためのエリスロポエチンの局所適用および製剤 Download PDF

Info

Publication number
JP5553769B2
JP5553769B2 JP2010540059A JP2010540059A JP5553769B2 JP 5553769 B2 JP5553769 B2 JP 5553769B2 JP 2010540059 A JP2010540059 A JP 2010540059A JP 2010540059 A JP2010540059 A JP 2010540059A JP 5553769 B2 JP5553769 B2 JP 5553769B2
Authority
JP
Japan
Prior art keywords
epo
gel
wound
formulation
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010540059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507920A (ja
JP2011507920A5 (enExample
Inventor
アウグスティヌス・バーダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2011507920A publication Critical patent/JP2011507920A/ja
Publication of JP2011507920A5 publication Critical patent/JP2011507920A5/ja
Application granted granted Critical
Publication of JP5553769B2 publication Critical patent/JP5553769B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010540059A 2007-12-28 2008-12-20 皮膚創傷治癒のためのエリスロポエチンの局所適用および製剤 Active JP5553769B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07025167 2007-12-28
EP07025167.3 2007-12-28
PCT/EP2008/010978 WO2009083203A2 (de) 2007-12-28 2008-12-20 Topische anwendung und formulierung von erythropoietin für die wundheilung der haut

Publications (3)

Publication Number Publication Date
JP2011507920A JP2011507920A (ja) 2011-03-10
JP2011507920A5 JP2011507920A5 (enExample) 2011-05-06
JP5553769B2 true JP5553769B2 (ja) 2014-07-16

Family

ID=40751089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010540059A Active JP5553769B2 (ja) 2007-12-28 2008-12-20 皮膚創傷治癒のためのエリスロポエチンの局所適用および製剤

Country Status (11)

Country Link
US (1) US9101586B2 (enExample)
EP (1) EP2222327B1 (enExample)
JP (1) JP5553769B2 (enExample)
CN (1) CN101951944B (enExample)
AU (1) AU2008342920B2 (enExample)
BR (1) BRPI0821814A2 (enExample)
CA (1) CA2709545C (enExample)
DK (1) DK2222327T3 (enExample)
ES (1) ES2625145T3 (enExample)
RU (1) RU2465003C2 (enExample)
WO (1) WO2009083203A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5869219B2 (ja) 2007-08-16 2016-02-24 レメドー バイオメッド リミテッド 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
DK2590666T3 (en) 2010-07-06 2017-07-17 Augustinus Bader TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
WO2012031778A1 (de) 2010-09-12 2012-03-15 Augustinus Bader Verwendung von erythropoietin bei der heilung von wunden oder gewebedefekten ohne narbenbildung
WO2014078581A1 (en) * 2012-11-14 2014-05-22 Smith & Nephew, Inc. Stable thermolysin hydrogel
US11452698B2 (en) 2013-03-15 2022-09-27 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
EP2991663B1 (en) * 2013-04-30 2017-09-13 University of Southern California Accelerated healing of eye injuries by angiotensin peptides
WO2015075406A1 (en) * 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
CN107427559A (zh) * 2015-09-04 2017-12-01 赛巴纳医药有限公司 局部用红细胞生成素制剂和用其提高伤口愈合的方法及其美容用途
RU2611401C1 (ru) * 2015-10-28 2017-02-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ получения лекарственного средства с эритропоэтином местного действия
JPWO2017104725A1 (ja) * 2015-12-16 2018-10-04 第一三共株式会社 創傷治療剤
KR102499651B1 (ko) 2016-11-10 2023-02-13 에이에스씨 리제니티 리미티드 에리트로포이에틴-유래 분자를 함유하는 국소 적용을 위한 미용 제형
RU2679446C2 (ru) * 2017-03-16 2019-02-11 Алексей Валерьевич Люндуп Способ лечения синдрома диабетической стопы
GB201720320D0 (en) 2017-12-06 2018-01-17 Univ Of Sussex Tissue repair
RU2754383C1 (ru) * 2020-12-07 2021-09-01 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) Способ лечения неинфицированного послеоперационного раневого дефекта стопы при отсутствии признаков критической ишемии конечности у больных с нейропатической и нейроишемической формой синдрома диабетической стопы
CN112961821B (zh) * 2021-02-24 2023-05-30 四川大学华西医院 三维培养血管内皮细胞的方法
CN115177782B (zh) * 2021-04-02 2023-07-18 诺一迈尔(山东)医学科技有限公司 一种高透气、促愈合的液体创可贴及其制备方法
JP2025524577A (ja) 2022-06-29 2025-07-30 バイオステム テクノロジーズ，インコーポレイテッド 無傷中間海綿層を間に有する無傷ヒト羊膜－絨毛膜組織から調製される創傷治癒用の微粉化組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680422B2 (en) * 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
JP2000095678A (ja) * 1998-09-22 2000-04-04 Dai Ichi Kogyo Seiyaku Co Ltd パップ剤用基剤およびそれを含有するパップ剤
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2003253015A1 (en) * 2002-06-20 2004-01-06 Bionethos Holding Gmbh Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure
DE10260873A1 (de) * 2002-12-23 2004-07-15 Beiersdorf Ag Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
EP1548031A1 (en) * 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
BRPI0418326A (pt) * 2003-12-30 2007-05-02 Bionethos Holding Gmbh método de regeneração de tecidos
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
WO2005070451A1 (en) 2004-01-22 2005-08-04 Zafena Aktiebolag Pharmaceutical composition comprising non-glycosylated erythropoietin
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
WO2006089056A2 (en) * 2005-02-16 2006-08-24 Alza Corporation Apparatus and method for transdermal delivery of erythropoetin-based agents
US20080247987A1 (en) * 2005-08-04 2008-10-09 Angiotech International Ag Block Copolymer Compositions and Uses Thereof

Also Published As

Publication number Publication date
EP2222327B1 (de) 2017-02-15
CN101951944A (zh) 2011-01-19
RU2465003C2 (ru) 2012-10-27
AU2008342920B2 (en) 2014-09-18
DK2222327T3 (en) 2017-05-15
CN101951944B (zh) 2015-04-01
AU2008342920A1 (en) 2009-07-09
WO2009083203A3 (de) 2010-02-18
US9101586B2 (en) 2015-08-11
US20100278916A1 (en) 2010-11-04
RU2010130890A (ru) 2012-02-10
JP2011507920A (ja) 2011-03-10
EP2222327A2 (de) 2010-09-01
CA2709545A1 (en) 2009-07-09
BRPI0821814A2 (pt) 2015-06-16
ES2625145T3 (es) 2017-07-18
WO2009083203A2 (de) 2009-07-09
CA2709545C (en) 2013-10-29

Similar Documents

Publication Publication Date Title
JP5553769B2 (ja) 皮膚創傷治癒のためのエリスロポエチンの局所適用および製剤
JP7013336B2 (ja) インサイチュー架橋性ポリマー組成物およびその方法
US7208179B1 (en) Methods for treating disease and forming a supplemented fibrin matrix
USRE39192E1 (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) Method of preparing a tissue sealant-treated biomedical material
JP2617260B2 (ja) 創傷治療用ゲル配合物
BRPI0717734B1 (pt) Método para preparar um pó seco de nanopartículas poliméricas, pó seco e uso do mesmo
Bhatnagar et al. Delivery systems for platelet derived growth factors in wound healing: A review of recent developments and global patent landscape
JP2012162561A (ja) キセロゲルまたはフィルムの形態での局所使用のための医薬組成物および製造方法
US20230372579A1 (en) Methods for treating wounds
AU2010335066A1 (en) Topical oral gel formulations for dental use
RU2699362C2 (ru) Композиция на основе наночастиц диоксида церия и полисахаридов бурых водорослей для лечения ран
US7112320B1 (en) Solid wound healing formulations containing fibronectin
KR100978905B1 (ko) 창상용 외용제
CN115336410B (zh) 一种生物制品dbt
ES2244689T3 (es) Parche cicatrizante hidrocoloidal que contiene acido hialuronico y sulfato de condroitina.
CN121081602A (zh) SjP40蛋白的应用、促进皮肤组织修复的组合物及其制备方法、药物制剂
CN114712391A (zh) 一种用于治疗外科局部感染的海藻酸钙-鱼石脂贴
RO128972B1 (ro) Membrană de colagen cu doxiciclină pentru uz stomatologic şi procedeu de obţinere a acesteia
Alvarez et al. Local care of diabetic foot ulcers: Assessment, dressings, and topical treatments
Smrke et al. The Role of Acellular Flowable Matrix in Tissue Regeneration
Gumenyuk et al. MODERN CHITOSAN-BASED WOUND DRESSINGS IN LOCAL WOUND TREATMENT: PRECLINICAL STUDIES
HK1240851A1 (en) Compositions for treating wounds
RU2019103612A (ru) Композиции и применение противомикробных материалов со свойствами биологической совместимости
AU5053200A (en) Supplemented and unsupplemented tissue sealants, methods of their production and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130305

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140527

R150 Certificate of patent or registration of utility model

Ref document number: 5553769

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250